AIDS VACCINE 2001 September 5-8, 2001 Philadelphia Marriott, PA, USA

Jump to Schedule: Wednesday, Sept. 5 Thursday, Sept. 6 Friday, Sept. 7 Saturday, Sept. 8

5-7 pm

1. Opening Session

Session Chairs: David Baltimore, California Inst. of Technology, Pasadena, USA and Salim Karim, Univ. of Natal, Durban, South Africa

Greetings from Program Committee Chair, Beatrice Hahn, Univ. of Alabama at Birmingham, USA

Keynote Lecture

The Global Need for an AIDS Vaccine
William Foege, Rollins Sch. of Publ. Hlth. of Emory Univ. and Senior Hlth. Advisor, Bill & Melinda Gates Fndn., Atlanta, GA, USA

Keynote Lecture

NIAID and Vaccine Research: Science and Policy
Anthony Fauci, NIAID/NIH, Bethesda, MD, USA

7:30-10 pm

Opening Reception

Session Chairs: Douglas Richman, Univ. of California, San Diego, USA and N. K. Ganguly, India Council on Med. Res., Ministry of Hlth. and Family Welfare, New Delhi, India

8-8:45 am

2. Plenary
Lessons from Acute Infection and
Relevance to Vaccine Development
Ashley Haase, Univ. of Minnesota, Minneapolis, USA

8:45-9:30 am

3. Plenary
Innate Immunity
Bruce Beutler, Scripps Inst., La Jolla, CA, USA

10 am - 1 pm

4. Slide Session
Candidate Vaccines I
Moderators: Dan R. Littman, Skirball Inst. of Biomolecular Med., New York Univ. Med. Ctr., NY, USA and Frances Gotch, Imperial Coll. Sch. of Med., London, UK

5. Slide Session
Virology
Moderators: Francine McCutchan, Henry M. Jackson Fndn., Rockville, MD, USA and Larry Arthur, NCI, Frederick, MD, USA

6. Slide Session
Access and Implementation
Moderators: Jorge Beloqui, Group for Life Incentive (GIV), São Paulo, Brazil

7. Slide Session
Molecular Epidemiology
Moderators: Saladin Osmanov, UNAIDS and World Hlth. Organization, Geneva, Switzerland

8. Slide Session
T-Cell Responses to Novel Immune Responses
Moderators: Irv Weisman, Stanford Univ., CA, USA and Frank Miedema, Univ. of Amsterdam/CLB

9. Slide Session
Animal Models
Moderators: John Shiver, Merck Res. Labs, West Point, PA, USA and Harriet Robinson, Yerkes Reg. Primate Res. Ctr. of Emory Univ., Atlanta, GA, USA

10. Slide Session
Human Trials I
Moderators: Andrew McMichael, John Radcliffe Hosp., Oxford, UK

2:30-4:30 pm

11. Symposium - Novel Envelope Immunogens
Conveners: Joseph Sodroski, Dana Farber Cancer Inst., Boston, MA, USA and Carolyn Williamson, Univ. of Cape Town, Observatory, South Africa

Neutralization of HIV-1
David Montefiori, Duke Univ. Med. Ctr., Durham, NC, USA

Studies on Disulfide-Stabilized Forms
of the HIV-1 Envelope Glycoproteins
John Moore, Cornell Univ., New York, NY, USA

Binding of Neutralizing Antibodies to
HIV-1 Envelope Complexes
Dennis Burton, Scripps Inst., La Jolla, CA, USA

Proteoliposomes Containing HIV-1 Envelope Glycoproteins
Richard Wyatt, NIH Vaccine Res. Ctr., Bethesda, MD, USA


12. Symposium - Experiences with Clinical AIDS Vaccine Trials in Humans: What We've Learned
Convener: Larry Corey, Univ. of Washington, Seattle and
HIV Vaccine Trials, Network, USA

Clinical Evaluation of an HIV-1 Clade A DNA/MVA Vaccine Designed for Kenya
Matilu Mwau, Univ. of Oxford, UK

Immunogenicity of Canarypox Vector Vaccines to HIV-1: A Review of Four Years of Trials
M. Juliana McElrath, Univ. of Washington, Seattle, USA

Cross Clade CTL Responses among
Recipients of Pox Virus Vaccines
Kent Weinhold, Duke Univ. Med. Ctr., Durham, NC, USA

Viral Diversity and Vaccine Considerations
Bette Korber, Los Alamos Natl. Lab., NM, USA

The Preclinical Pipeline
Margaret Johnston, DAIDS, NIAID, NIH, Bethesda, MD, USA

4:30 pm – 6:30 pm

13. Poster Session
T-Cell Epitope Mapping

14. Poster Session
Mucosal Immune Responses

15. Poster Session
Cytokines

16. Poster Session
Cross-Clade Immune Responses

17. Poster Session
CTL Escape

18. Poster Session
Assay Development: CTL

19. Poster Session
Assay Development: Neutralizing Antibodies

20. Poster Session
Assay Development: Carbohydrate-Based Microarray

21. Poster Session
Assay Development: Subtype Classifications

22. Poster Session
Basic Virology

23. Poster Session
Cellular Receptors

24. Poster Session
Envelope Structure/Function/Novel Immunogens

25. Poster Session
Acute Infection

26. Poster Session
Determinants of HIV Disease Progression

27. Poster Session
Susceptibility of HIV/SIV Infection

28. Poster Session
NK Cell Activity

29. Poster Session
HAART and Immune Responses

30. Poster Session
Animal Models: Primates

31. Poster Session
Animal Models: Mice

32. Poster Session
Animal Models: Horses

33. Poster Session
Animal Models: Rabbit

34. Poster Session
DNA Vaccines

35. Poster Session
Live Attenuated Vaccines

36. Poster Session
Whole Inactivated Virus Vaccines

37. Poster Session
Dendritic Cell-Based Vaccines

38. Poster Session
Synthetic Vaccines

39. Poster Session
Peptide Immunogens

40. Poster Session
Novel Vectors

41. Poster Session
Pox Virus Vectors

42. Poster Session
Adjuvants

43. Poster Session
Safety and Immunogenicity: Phase I/II Trials

44. Poster Session
Phase III Efficacy Trials

45. Poster Session
Therapeutic Vaccination

46. Poster Session
Database and Mathematical Modeling

47. Poster Session
Epidemiology

48. Poster Session
HIV Molecular Biology

49. Poster Session
HIV-1 Subtypes

50. Poster Session
HIV-1 Recombination

51. Poster Session
Infrastructure Development

52. Poster Session
Access and Implementation

5:30-7 pm

53. Special Workshop - Orientation to Working with the U.S. FDA

Overview of the IND Process
Speaker TBD

Hot Button IND Issues
Rebecca Sheets, CBER/FDA, Rockville, MD, USA

How to Plan For/Set Up Your Pre-IND Meeting
Stuart Shapiro, Vaccine Res. Branch, DAIDS, NIAID, NIH, Bethesda, MD, USA

Panel Discussion

Session Chairs: Mauro Schechter, Univ. Federal do Rio de Janeiro, Brazil and Neal Nathanson, Univ. of Pennsylvania, Philadelphia, USA

8-8:45 am

54. Plenary
South Africa: A Case Study in Vaccine Implementation
William Magkoba, Med. Res. Council of South Africa, Cape Town

8:45-9:30 am

55. Plenary
Lessons from the Monkey
Norman Letvin, Beth Israel-Deaconess Med. Ctr., Harvard Med. Sch., Boston, MA, USA

10 am - 1 pm

56. Slide Session
Innovative Approaches to HIV Vaccine Research: Highlighted NIAID Innovation Grants
Moderators: James Bradac, NIAID, NIH, Bethesda, MD, USA and Jamie Scott, Simon Fraser Univ., Burnaby, British Columbia, Canada

57. Slide Session
Candidate Vaccines II
Moderators: Thomas Lehner, Guy's King's & St. Thomas' Hosp. Med. Sch., London, UK and Robert B. Couch, Baylor Coll. of Med., Houston, TX, USA

58. Slide Session
Antibodies and Cytokines
Moderators: Peter Wright, Vanderbilt Univ. Med. Ctr., Nashville, TN, USA and Susan Zolla-Pazner, New York Univ. Sch. of Med., NY, USA

59. Slide Session
Human Trials II
Moderators: Raphael Dolin, Harvard Med. Sch., Boston, MA, USA

60. Slide Session
HIV Evolution
Moderators: Leopold Zekeng, Ministry of Hlth., Yaounde, Cameroon

61. Slide Session
Pathogenesis
Moderators: Françoise Barré-Sinoussi, Unité de Biologie des Rétrovirus, Inst. Pasteur, Paris, France and Martin Markowitz, Aaron Diamond AIDS Res. Ctr., New York, NY, USA

2:30-4:30 pm

62. Symposium - Design, Oversight, and Review of Phase III Efficacy Trials
Convener: Tim Mastro, CDC, Atlanta, GA, USA and Kachit Choopanya, Bangkok, Thailand

The AIDSVAX B/B Phase III Efficacy Trial in North America and The Netherlands
Donald Francis, VaxGen Inc., Brisbane, CA, USA

Thailand's Success in Moving to a
Phase III HIV Vaccine Trial
Punnee Pitisuttithum, Mahidol Univ., Bangkok, Thailand

The US Army's Plans for Phase III HIV Vaccine Trials
Debbie Birx, Walter Reed Army Inst. of Res., Rockville, MD, USA

Plans for an HIV Vaccine Efficacy Trial
in the NIH HIV Vaccine Trials Network
Susan Buchbinder, San Francisco Dept. of Publ. Hlth., CA, USA


63. Symposium - Global Challenges for Vaccine Implementation
Conveners: Bill Snow, AIDS Vaccine Advocacy Coalition, Berkley, CA, USA and Seth Berkley, Intl. AIDS Vaccine Initiative, New York, NY, USA

Regional and Country International Vaccine Development Plans
Jose Esparza , UNAIDS and World Hlth. Organization, Geneva, Switzerland

Community Participation
Steve Wakefield, Community Ed., HIV Vaccine Trials Network, Seattle, WA, USA and Janet Froelich, Community Advisory Board, HIV Vaccine Trials Network, Durban, South Africa

Ethics
Zeke Emanuel, NIH Bioethics Group, Bethesda, MD, USA

Access Issues, Demand, Pricing and Financing
David Gold, Intl. AIDS Vaccine Initiative, New York, NY, USA

4:30 pm – 6:30 pm

52. Poster Sessions
See Thursday, September 6, for listing

7:30-9:30 pm

Social Event